

The new Dysfunctional Personality Model of the Dramatic Matrix (DPM-DM) and the Psychotic Matrix (DPM-PM): “Dramatic Personality Disorder” (DPD) and “Psychotic Personality Disorder” (PPD)

Giulio Perrotta

Istituto per lo Studio delle Psicoterapie (ISP), 00185, Rome (Italy).

***Corresponding Author:** Giulio Perrotta, Istituto per lo Studio delle Psicoterapie (ISP), 00185, Rome (Italy).

Received date: October 07, 2024; **Accepted date:** October 17, 2024; **Published date:** October 23, 2024

Citation: Giulio Perrotta, (2024), The new Dysfunctional Personality Model of the Dramatic Matrix (DPM-DM) and the Psychotic Matrix (DPM-PM): “Dramatic Personality Disorder” (DPD) and “Psychotic Personality Disorder” (PPD), *Psychology and Mental Health Care*, 8(8): DOI:10.31579/2637-8892/308

Copyright: © 2024, Giulio Perrotta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

According to the PICI model, there are six personality disorders in the neurotic area (anxious, phobic, obsessive, somatic, avoidant, and manic), and the diagnosis of psychopathological disorder is determined based on the persistence of certain dysfunctional traits present in the personality framework. Based on clinical experience and through the application of the IPM/PICI, Deca, PDM, PHEM and PPP-DNA models, it was found that all disorders in the neurotic area had anxiety traits in common and that symptoms of the six different disorders were often present in comorbidity. This assumption led to the hypothesis of a different and better way to group them into one all-encompassing category: "Neurotic Personality Disorder" (NPD). Based on this construct, it is suggested to perform the same nosographic operations for the other personality disorders, grouping 7 personality disorders (bipolar, depressive, borderline, histrionic, narcissistic, antisocial, psychopathic) from the psychopathological area related to Cluster B of DSM-5-TR and PICI-3 into "Dramatic Personality Disorder" (DPD) and 4 other personality disorders (delusional, paranoid, dissociative, schizophrenic spectrum) from the psychopathological area related to Cluster A of DSM-5-TR and Cluster C of PICI-3 into "Psychotic Personality Disorder" (PPD). This paper aims to suggest their use to facilitate psychopathological framing.

Keywords: neurotic personality disorder; anxiety; Panic; mania; obsession; compulsion; avoidance; phobia; dramatic personality disorder; bipolar; depressive; borderline; histrionic; narcissistic; antisocial; psychopathic; psychotic personality disorder; delirium; hallucination; paranoia; dissociation; pici-3

1. Introduction

The heterogeneous and intangible nature of psychiatric symptomatology has always generated problems of diagnostic certainty, in the absence of the use of biochemical laboratory parameters or instrumental examinations. To solve this clinical dilemma, already since the end of the first half of the last century, an attempt has been made to apply a rigid, nosographic approach in the classification of psychiatric disorders, so that a more objective diagnosis can be made, despite the limitations brought about by the rigidity of the method of investigation. Although diagnostic techniques have been perfected over the decades, including the use of validated psychometric instruments, several critical issues persist today that deserve attention. Currently, in psychiatry there are several classification methods, generally recognized by the scientific community, and the most widely used are the Diagnostic and Statistical Manual of

Mental Disorders (DSM-5-TR) compiled by the American Psychiatric Association and the International Classification of Diseases (ICD-11) issued by the World Health Organization, in addition to the attempt made through the Psychodynamic Diagnostic Manual (PDM-II) of the International Psychoanalytical Association, with a clear psychoanalytic matrix. [1-5]

Based on the need for greater awareness of psychopathological diagnosis and based on 5 basic principles, underlying the "Integrated Psychodynamic Model" (IPM) and the "Perrotta Integrative Clinical Interviews" (PICI) [6-13], now in the third version (PICI-3) [14], the "Decagonal Model" (Deca-Model) [15-16], the "Perrotta Defense Mechanisms (PDM)" [17-18], now in second revised version [19], and

the "Perrotta Human Emotions Model" (PHEM) [20], now in second version [21], a new construct was identified that could reorganize the nosographic interpretation of neurotic area disorders, based on the "Perrotta Psychotherapeutic Protocol for Disorders of the Neurotic Area" (PPP-DNA). This new construct, crystallized in the "Dysfunctional Personality Theory of the Neurotic Matrix" (DPT-NM) and then in the corresponding model ("Dysfunctional Personality Model of the Neurotic Matrix", DPM-NM) was called "Neurotic Personality Disorder" (NPD) [22], with the characteristics of being able to distinguish between 6 specificities (Anxious, Phobic, Avoidant, Somatic, Obsessive and Manic) and several sub typicalities.

This construct, for the same needs, can also be extended to disorders not included in the neurotic area.

2. Dysfunctional Personality Model of the Dramatic Matrix (DPM-DM) and the Dramatic Matrix (DPD)

As with the neurotic model [22], a new restructuring of the individual types afferent to the dramatic area personality disorder is provided for the dramatic model (according to the DSM-5-TR) [23-103]. Based on the construct, below is the outline of the dysfunctional personality model that justifies the nosographic innovation of the matrix of "Dramatic Personality Disorder" (DPD) [Table 1].

<i>Primary Disorder</i>	<i>Type or Specifications (of traits)</i>	<i>Sub-types</i>	<i>Description</i>
Dramatic Personality Disorder	<i>Bipolar</i> [104]	Manic-depressive (or type I)	The subject has been suffering for more than 6 months from a manic-depressive condition, characterized by the alternation of medium-long cycles of manic and depressive moods, capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and that worsen the quality of life.
		Manic-dysthymic (or type II)	The subject has been suffering for more than 6 months from a manic-dysthymic condition, characterized by alternating medium-long cycles of manic and dysthymic, capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and that worsen the quality of life.
		Depressive-Hypomanic (or type III)	The subject has been suffering for more than 6 months from a hypomanic-depressive condition, characterized by alternating medium-long cycles of hypomanicity and depression, capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and that worsen the quality of life.
		Hypomanic - dysthymic (or type IV)	The subject has been suffering for more than 6 months from a hypomanic-dysthymic condition, characterized by alternating medium-long cycles of hypomanicity and dysthymia, capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and that worsen the quality of life.
		Mixed form (or type V)	The subject has been suffering for more than 6 months from a hypomanic-depressive condition, characterized by alternating medium-to-long cycles of mixed forms of manic/hypomanicity and depression/dysthymia, capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and worsen the quality of life.
	<i>Depressive</i> [105-106]	Sub-clinical (or type I)	The person has been suffering from a potentially clinically interesting condition for less than 30 days, in which he or she manifests depressive symptoms but in a milder or less impactful form than depressive disorders (e.g., premenstrual dysphoria, occasional seasonal dysphoria, adjustment deficit, brief depressive episode of less than 30 days). This condition is capable of negatively impacting one or more complex spheres of his or her existence (personal, social, emotional, work,...), with

			symptoms that do not spontaneously regress and worsen the quality of life.
		Reactive (or type II)	The subject has been suffering for less than 12 months from a reactive or situational condition that results in depressive symptoms of clinical interest and stems from an adjustment disorder that has been active and unprocessed for at least 30 days (e.g., events during pregnancy, separation stressors or hypercontrol in postpartum, prolonged seasonal dysphoria, persistent bereavement with depressive symptoms for less than 1 year, maladjustment to the traumatic event). This condition is capable of negatively impacting one or more complex spheres of his or her existence (personal, social, emotional, work,...), with symptoms that do not spontaneously regress and worsen the quality of life.
		Dysthymic (or type III)	The subject has been suffering for less than 2 months from a dysthymic condition resulting in depressive symptoms of clinical interest. This condition is capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and worsen the quality of life.
		Chronic or Major (or type IV)	The subject has been suffering for more than 2 months from a dysthymic condition resulting in depressive symptoms of clinical interest. This condition is capable of negatively impacting one or more complex spheres of his or her existence (personal, social, affective, work,...), with symptoms that do not spontaneously regress and worsen the quality of life.
		Mixed “typical” form (or type V)	They are conditions of clinical interest, with a specificity different from the pure forms of depressive conditions and depressive disorder. They have a wide negative impact on the patient's life, such that their functioning is impaired to a large extent and they cause psychophysical distress and malaise.
		Mixed “atypical” form (or type VI)	These are conditions of clinical interest, where the patient manifests depressive symptoms, without fully meeting all criteria or only the structural criterion, but at a more severe level than the subclinical form. They have an extensive negative impact on the patient's life, such that his or her functioning is impaired to a large extent and he or she perceives psychophysical distress and discomfort.
	<i>Borderline</i> [104, 107]	Unstable-impulsive (or type I)	The subject has been suffering for more than 6 months from a clinically relevant condition characterized by emotional instability, impulsivity, and irrational fear of being abandoned, forgotten, or betrayed (in the absence of psychotic symptoms). This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Aggressive-explosive (or type II)	The person has been suffering for more than 6 months from a clinically relevant condition characterized by unwarranted fear for self or others (in the absence of psychotic symptoms) and marked explosive aggression, under circumstances that are not objectively justifiable. This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Emotional-humoral (or type III)	The person has been suffering from a clinically relevant condition for more than 6 months, characterized by a marked mood sensitivity that tends toward emotional fragility and need for attention, under circumstances that are not objectively justifiable. This condition involves one or more complex spheres

			of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Deflected (or type IV)	The subject has been suffering from a clinically relevant condition for more than 6 months, characterized by a marked mood sensitivity that tends toward emotional fragility, and a need for protection from the surrounding world, with a negative and deflected mood most of the time, in the absence of clinically relevant depressive symptoms. This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Fragmented (or type V)	The subject has had a clinically relevant condition for more than 6 months, characterized by marked mood sensitivity tending toward emotional fragmentation, in the absence of clinically relevant psychotic symptoms. The perceptual plane is distorted but without psychotic episodes. This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Mixed (or type VI)	The subject has been suffering for more than 6 months from a clinically relevant condition, characterized by a multitude of borderline features in the various typifications, but without remaining marked on a specific one, for at least 5 years. Single brief episodes do not fall into the present category but are representations of overactivations in any case not exceeding 15-30 days. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not regress spontaneously, worsening the quality of life.
	<i>Histrionic</i> [108]	Concentrator (or type I)	The subject has been suffering for more than 6 months from a clinically relevant condition characterized by the need to centralize attention on oneself, in the absence of psychotic symptoms (delusions) and the absence of narcissistic behavior (manipulation to the detriment of others for one's advantage). Reasons for need may vary according to personality profile and may depend on caretaking needs, more or less conscious simulations. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Manipulative (or type II)	The subject has been suffering for more than 6 months from a clinically relevant condition characterized by the use of manipulation and lying, in the absence of psychotic symptoms (delusions) and in the absence of narcissistic behavior (manipulation to the detriment of others for one's advantage). This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Fascinator (or type III)	The subject has been suffering for more than 6 months from a clinically relevant condition characterized by the need to use one's oratorical, communicative, and intellectual arts to charm, in the absence of psychotic symptoms (delusions) and the absence of narcissistic behavior (manipulation to the detriment of others for one's advantage). This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.

		Seductive (or type IV)	The person has been suffering for more than 6 months from a clinically relevant condition, characterized by a need to use his or her body and sense for personal advantage, in the absence of psychotic symptoms (delusions) and the absence of narcissistic behavior (manipulation to the detriment of others for one's advantage). This condition involves one or more complex spheres of his or her existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
		Mixed form (or type V)	The subject has been suffering for more than 6 months from a clinically relevant condition, characterized by a variety of histrionic symptoms that cannot be attributed exclusively to one type, but always in the absence of psychotic symptoms (delusions) and narcissistic behavior (manipulation to the detriment of others for one's advantage). This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life.
	<i>Narcissistic</i> [109-110]	Infantilism (or type I)	The person exhibits childish attitudes and behaviors, relative to age and context, consisting of poor intellectual and emotional maturity. This condition involves one or more complex spheres of his or her existence (personal, family, social, work), leading to a deterioration in the quality of life.
		Selfishness (or type II)	The person exhibits selfish attitudes and behaviors, in comparison with social expectation, age and reference context, consisting of over-characterization of his own needs compared to those of the people around him. This condition involves one or more complex spheres of his existence (personal, family, social, work), leading to a worsening of the quality of life.
		Egocentrism (or type III)	The subject exhibits egocentric attitudes and behaviors, concerning social expectation, age and context of reference, consisting of over-characterization of his own needs for those of the people around him, to their detriment (to selfishness that is realized without the need to take advantage of others' subjective positions). This condition involves one or more complex spheres of his existence (personal, family, social, work), leading to a worsening of the quality of life.
		Narcissism-Overt (or type IV)	The subject has had a clinically relevant condition for more than 6 months and he presents egocentric attitudes and behaviors, concerning social expectation, age and context of reference, consisting of the use of active manipulation, the need to establish superficial and functional ties to obtain personal goals, to the detriment of others, needs for admiration and power, high self-esteem often unmotivated, arrogance and sense of superiority. This condition involves one or more complex spheres of his or her existence (personal, family, social, work), leading to a deterioration in the quality of life.
		Narcissism-Covert (or type V)	The subject has had a clinically relevant condition for more than 6 months and he presents egocentric attitudes and behaviors, concerning social expectation, age and context of reference, consisting of the use of passive-aggressive manipulation, the need to establish bonds of control and dependence, even fictitious ones, need for attention and reassurance, low self-esteem often unmotivated or feigned only to attract attention, use of grievance and guilt to obtain one's advantages. This condition involves one or more complex spheres of his or her existence (personal, family, social, work), leading to a worsening quality of life.

	Narcissism- Mixed (or type VI)	The subject presents egocentric attitudes and behaviors, concerning social expectation, age and reference context, consisting of both overt and covert narcissistic modes, without a specific predominance or exclusively related to situational overactivations. This condition involves one or more complex spheres of his or her existence (personal, family, social, work), leading to a worsening quality of life.
<i>Antisocial</i> [111-112]	Deviant (or type I)	The subject manifests conduct in violation of social norms, which exposes him or her to the judgment of the relevant community. He tends to maintain a generally expected profile, even if he is considered by his environment to be a rebel or a compliant person, without, however, violating any legal norms or of low value to the criminal system. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the consequences make the quality of life worse.
	Criminal (or type III)	The individual manifests conduct in violation of legal norms, which exposes him or her to the judgment of the relevant community and criminal sanctions of a punitive nature (economic and/or imprisonment of one's personal freedom). He fails to maintain a generally expected profile and is considered a criminal by his environment. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the consequences make the quality of life worse.
<i>Psychopathic</i> [111-112]		The subject has been affected for more than 6 months by a constellation of specific affective, interpersonal, and behavioral characteristics, such as superficial charm, lack of empathy, the grandiosity of self, arrogance and haughtiness, need for continuous stimulation, pathological lying, manipulation use of violence, antisociality, behavioral dyscontrol, low tolerance of frustration with aggressive behavior in the face of criticism and failure, associated with high irritability and anger dysregulation, promiscuous sexual behavior, and early behavioral problems: all of which recall the instability of the borderline, the criminal behaviors of the antisocial, the fascination of the histrionic and the grandiosity of the narcissist, via the mood swings of the bipolar and the deflections of the depressed. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the consequences make the quality of life worse.
<i>Mixed form</i>		The subject presents a constellation of symptoms reminiscent of two or more types of disorders, but without having a specific characterization. Mixed forms are characterized by being the result of two distinct profiles, unlike psychopathy, which has a multitude of symptoms but the predominance is antisociality and grandiosity, in essence, a narcissistic-antisocial condition with the presence of borderline, bipolar and histrionic features. The multiplicity of symptoms may also involve the neurotic and/or psychotic spectrum.

Table 1: Dramatic Personality Disorder (DPD).

3. Dysfunctional Personality Model of the Psychotic Matrix (DPM-PM) and the Psychotic Matrix (PPD)

As with the neurotic model [22], a new restructuring of the individual types afferent to the psychotic area personality disorder is provided for

the psychotic model (according to the DSM-5-TR) [113-127]. Based on the construct, below is the outline of the dysfunctional personality model that justifies the nosographic innovation of the matrix of "Psychotic Personality Disorder" (PPD) [Table 2]. For all types of the psychotic spectrum the specifiers are applicable [Table 3].

<i>Primary Disorder</i>	<i>Type or Specifications (of traits)</i>	<i>Sub-types</i>	<i>Description</i>
Psychotic Personality Disorder [128-130]	<i>Delusional</i>	-	The subject has been suffering for more than 1 month from a clinically relevant condition characterized by one or more false or erroneous beliefs held firmly, in the presence of a real stimulus and concerning facts existing in real life, even though there are elements that disconfirm one's interpretation of reality. When the delirium becomes structured in a resistant form and occurs in the absence of any real external stimulus, coloring itself with mysterious, magical, bizarre, extravagant scenarios devoid of any concrete or realistic foothold (in the absence of hallucinations), and thus is not the mere exaggeration of a real or otherwise realistic fact, it assumes the designation of "paranoia". The content of the delirium may take a variety of forms and contents (e.g., somatic delirium, religious delirium, nihilistic delirium, persecutory delirium, love delirium, sexual delirium, megalomania, delirium of guilt or sin) but never must have a bizarre and/or extravagant orientation (e.g., paranormal phenomena and/or extrasensory powers), in the absence or presence of altered perceptual states. In no case should there be any hallucination phenomena (understood as false perception in the absence of a real stimulus), Otherwise, the schizophrenic spectrum hypothesis should be considered. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life. The duration of less than 1 month, and it is not recurrent, defines the diagnosis of a "delusional episode or psychotic slip of the delusional type".
	<i>Dissociative</i>	Internal	The subject has been suffering for more than 1 month from a clinically relevant condition characterized by one or more dissociative episodes, related to experiences of depersonalization (understood as perceptions of disconnection from one's body or mental processes, as if one were observing one's life from the outside). The subject feels detached from body, mind, feelings and/or sensations. The subject may also report feeling out of reality or like an automaton, with no control over what he or she does or says, and may feel emotionally or physically numb. In these cases, the subject may describe himself as an outside observer of his own life, or as a "dead man walking". If he or she presents bizarre and/or extravagant content one must refer to the schizophrenic spectrum in diagnosis. If it presents hallucinatory phenomena one must refer, in diagnosis, to complicated internal dissociative disorder. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not regress spontaneously, worsening the quality of life. The duration of less than 1 month, and it is not recurrent, defines the diagnosis of a "depersonalizing dissociative episode or psychotic slip of the internal dissociative type", complicated or not if there is the presence of hallucinations and there are no extremes for the diagnosis of schizophrenic spectrum.
		External	The subject has been suffering for more than 1 month from a clinically relevant condition characterized by one or more dissociative episodes, related to experiences of derealization (understood as perceptions of detachment from the surrounding environment, including people and things, with a marked feeling of un-reality). If it presents bizarre and/or extravagant content, one must refer to the schizophrenic spectrum in diagnosis. If it presents hallucinatory phenomena one must refer, in diagnosis, to complicated external dissociative disorder. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not regress spontaneously, worsening the quality of life. The duration of less than 1 month, and it is not recurrent,

		defines the diagnosis of a "derealizing dissociative episode or psychotic slip of the external dissociative type", complicated or not if there is the presence of hallucinations and there are no extremes for the diagnosis of schizophrenic spectrum.
	Mixed dissociative form	The subject has been suffering for more than 1 month from a clinically relevant condition characterized by a mixed form of the previously described symptoms related to internal and external dissociative disorders. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not spontaneously regress, worsening the quality of life. A duration of less than 1 month defines the diagnosis of a "dissociative episode or psychotic slippage of dissociative type", complicated or not if there is the presence of hallucinations and there are no extremes for the diagnosis of the schizophrenic spectrum.
	Fragmentation of identity	The subject manifests a clinically relevant condition characterized by the presence of one or more personalities, with speech, temperament, and behavior patterns also different from those normally associated with the subject. Each personality may present specific functional and dysfunctional traits, and they should be studied individually. This condition involves one or more complex spheres of his or her existence (personal, family, social, work), and the symptoms do not regress spontaneously, worsening the quality of life. In this condition, there is no time limit for the manifestation of symptoms, and even a single event is assessable according to the pattern of psychotic personality disorder, dissociative type, and fragmentary subtype of identity.
<i>Schizophrenic spectrum</i>	Schizoid	The subject has been manifesting for more than 1 month a clinically relevant condition characterized by a pervasive pattern of general detachment and disinterest in social relationships and a limited range of emotions in interpersonal relationships. Any delusional, paranoid, and/or dissociative content should be evaluated based on the complexity of the pathological form. The presence of hallucinations orients the diagnosis in pure subtype schizophrenic spectrum disorder. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not regress spontaneously, worsening the quality of life. Duration of less than 1 month defines the diagnosis of a "schizoid episode or schizoid-like psychotic slip".
	Schizotypal	The subject has been manifesting for more than 1 month a clinically relevant condition characterized by a pervasive pattern of intense distress and reduced capacity for close relationships, alterations in thinking and perceptions, and eccentric behavior. These patients often misinterpret daily episodes as having special meaning for them (ideas of reference). They may be superstitious or think they have special paranormal powers that enable them to perceive events before they happen or to read the minds of others. They may think that they have magical control over others, thinking that they can cause other people to experience everyday events (e.g., feeding the dog), or that performing magical rituals can prevent harm (e.g., washing hands 3 times can prevent illness). Any delusional, paranoid, and/or dissociative content should be evaluated based on the complexity of the pathological form. The presence of hallucinations orients the diagnosis in pure subtype schizophrenic spectrum disorder. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symptoms do not regress spontaneously, worsening the quality of life. The duration of less than 1 month defines the diagnosis of "schizotypal episode or psychotic slippage of schizotypal type".
	Schizoaffective	The subject has been manifesting for more than 1 month of a clinically relevant condition characterized by a pervasive pattern manifesting psychotic symptoms and marked humor of unipolar (manic/depressive) or bipolar type. The presence of hallucinations directs the diagnosis into pure

			subtype schizophrenic spectrum disorder. This condition involves one or more complex spheres of his existence (personal, family, social, work) and the symp-toms do not regress spontaneously, worsening the quality of life. The duration of less than 1 month defines the diagnosis of "schizo-affective episode or psychotic slip-page of schizo-affective type or mixed bipolar form complicated by psychotic symptoms".
		Pure (or Schizophrenia o Mixed form)	The subject has been manifesting for more than 1 month of a clinically relevant condition characterized by psychosis (loss of contact with reality), hallucinations (false perceptions), delu-sions/paranoia (false beliefs), disorganized language and behavior, flattening of affectivity (reduced emotional manifestations), cogni-tive deficits (impaired reasoning and problem-solving ability), and occupational and social malfunction. It represents the most severe form of psychotic disorder. This condition involves one or more complex spheres of existence (personal, family, social, occupa-tional) and symptoms do not spontaneously regress, worsening the quality of life. The duration of less than 1 month defines the diagnosis of an "episode of psychotic lability, with schizophrenic marking".
	<i>Psychotic mixed form</i>	-	The subject presents a constellation of symptoms reminiscent of two or more types of disorders, but without having a specific characterization. Mixed forms are characterized by being the result of two distinct profiles. The multiplicity of symptoms may also involve the neurotic and/or dramatic spectrum.

Table 2: Psychotic Personality Disorder (DPD).

<i>Specifier</i>	<i>Description</i>
<i>Primary disorder</i>	The symptomatology described by the patient or the patient's medical history is determined by the psychiatric illness and not by other secondary illnesses (e.g., dementia, cancer), drug use, or as a result of taking drugs that cause the symptoms.
<i>Secondary disorder</i>	The symptomatology described by the patient or the patient's medical history is not determined by the psychiatric illness but by other secondary illnesses (e.g., dementia, cancer), drug use, or as a result of taking drugs that cause the symptoms.
<i>Short Episode</i>	The psychotic episode, consisting mainly of one or more psychotic symptoms, has a total duration of less than or equal to 1 week, in continuous form.
<i>Recurring Episodes</i>	Psychotic episodes, consisting mainly of one or more psychotic symptoms, have a total duration of less than or equal to 1 month, even if not continuous.
<i>Chronic episode</i>	The psychotic episode, which consists mainly of one or more psychotic symptoms, has a total duration of more than 1 month, in continuous form.
<i>Presence or absence of hallucinations</i>	The patient has in his or her medical history one or more episodes, even if not continuous, of hallucinations, regardless of form and content.

Table 3: Specifiers of the “Psychotic Personality Disorder” (DPD).

4. Conclusion

This editorial completes the research work on the PPP-DNA clinical protocol of the nosographic hypothesis of "Neurotic Personality Disorder" (NPD), which is a synonym of cluster A according to the PICI model. According to what is reported in this publication, Cluster B of the same model can be named "Dramatic Personality Disorder" (DPD), while Cluster C can be named "Psychotic Personality Disorder" (PPD). Such new nosographies, with indications of the specific types and subtypes, have the task of facilitating the clinical interpretive process by encouraging a rationalization of structural and functional matrices (in dysfunctional terms) in psychodiagnostic terms. As was already the case with the research related to PPP-DNA and NPD, studies related to the diagnostic utility of these new nosographies are being carried out, using an adequate and representative population sample. Future perspectives

will therefore be related to the confirmation or not of the usefulness and thus the possible reorganization of the PICI-3, as a questionnaire to investigate functional and dysfunctional personality traits, into a more evolved and rational version (PICI-4).

References

1. Perrotta, G. (2019). *Psicologia clinica*. I ed., Luxco Ed.
2. Perrotta, G. (2019). *Psicologia generale*. I ed., Luxco Ed.
3. APA. DSM-V, (2013). *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Ed.
4. PDM Task Force. (2017) *Psychodynamic Diagnostic Manual*. Silver Spring, II ed., MD: *Alliance of Psychoanalytic Organizations*.
5. WHO Task Force. (2018). *ICD-11 - Mortality and Morbidity Statistics*. Icd.who.int.

6. Perrotta, G. (2021). "Perrotta Psychotherapeutic Protocol for Disorder of the Neurotic Area (PPP-DNA)": proposal of protocol, profiles and clinical applications. *Open J Trauma*; 5(1): 010-018. DOI: 10.17352/ojt.000037.
7. Perrotta, G.(2020). The structural and functional concepts of personality: The new Integrative Psychodynamic Model (IPM), the new Psychodiagnostic Investigation Model (PIM) and the two clinical interviews for the analysis of personality disorders (Perrotta Integrative Clinical Interview or PICI) for adults and teenagers (1TA version) and children (1C version). *Psychiatry Peertechz*; E-book. DOI: 10.17352/ebook10118.
8. Perrotta, G.(2020). First revision of the Psychodiagnostic Investigation Model (PIM-1R) and elaboration proposal of a clinical interview for the analysis of personality disorders (Perrotta Integrative Clinical Interview or PICI-1) for adults, teenagers and children, *Psychiatry Peertechz*; E-book. DOI: 10.17352/ebook10119.
9. Perrotta, G.(2020). "Perrotta Integrative Clinical Interview (PICI-1)": Psychodiagnostic evidence and clinical profiles in relation to the MMPI-II, *Ann Psychiatry Treatm*; 4(1): 062-069, DOI: 10.17352/apt.000022.
10. Perrotta, G.(2020). "Perrotta Integrative Clinical Interview" (PICI) for adults and teenagers (1TA version) and children (1C version): new theoretical models and practical integrations between the clinical and *psychodynamic approach*. *Ann Psychiatry Treatm*; 5(1): 001-014, DOI: 10.17352/apt.000024.
11. Perrotta, G. (2021.)Perrotta Integrative Clinical Interview (PICI-1): a new revision proposal for PICI-1TA. Two single cases. *Glob J Medical Clin Case Rep*, 8(1):041-049, DOI: 10.17352/2455-5282-000125.
12. Perrotta, G.(, 2021). Perrotta Integrative Clinical Interviews (PICI-2): innovations to the first model, the study on the new modality of personological investigation, trait diagnosis and state diagnosis, and the analysis of functional and dysfunctional personality traits. An integrated study of the dynamic, behavioural, cognitive and constructivist models in psychopathological diagnosis. *Ann Psychiatry Treatm*; 5(1): 067-083. DOI: 10.17352/apt.000033.
13. Perrotta, G.(2021). Perrotta Integrative Clinical Interviews (PICI-2), III ed., LK ed.
14. Perrotta, G. (2024)."Perrotta Integrative Clinical Interviews-3" (PICI-3): Development, regulation, updation, and validation of the psychometric instrument for the identification of functional and dysfunctional personality traits and diagnosis of psychopathological disorders, for children (8–10 years), preadolescents (11–13 years), adolescents (14–18 years), adults (19–69 years), and elders (70–90 years). *Ibrain*; 1-18. DOI: 10.1002/ibra.12148.
15. Perrotta, G.(2020). The strategic clinical model in psychotherapy: theoretical and practical profiles. *J Addi Adol Beh*, 3(1), DOI: 10.31579-007/2688-7517/ 016.
16. Perrotta, G.(2021).Strategic psychotherapy and the "decagonal model" in clinical practice. *Ann Psychiatry Treatm*; 5(1): 028-035. DOI: 10.17352/ apt.000028.
17. Perrotta, G.(2020). Human mechanisms of psychological defence: definition, historical and psychodynamic contexts, classifications and clinical profiles. *Int J Neurorehabilitation Eng*; 7:1, 1000360.
18. Perrotta, G.(2021). "Perrotta Human Defense Mechanisms Questionnaire" (PDM-Q): The new psychodiagnostic tool to identify human psychological defense mechanisms and their clinical implications. *Arch Depress Anxiety*; 7(2): 029-033. DOI: 10.17352/2455-5460.000063.
19. Perrotta, G.(2023). "Perrotta Human Defense Mechanisms Questionnaire (PDM-Q-v2)": Development, regulation and validation of a psychometric instrument for the identification of the functioning of individual Ego defense mechanisms. *Arch Depress Anxiety*; 9(2):072-078. DOI: 10.17352/2455-5460.000084.
20. Perrotta, G. (2021).The "Human Emotions" and the "Perrotta Human Emotions Model" (PHEM): The new theoretical model. Historical, neurobiological and clinical profiles. *Arch Depress Anxiety*; 7(2): 020-027. DOI: 10.17352/2455-5460.000062.
21. Perrotta, G.(2023). Basiletti, V.; Eleuteri, S. The "Human Emotions" and the new "Perrotta Human Emotions Model" (PHEM-2): Structural and functional updates to the first model. *Open J Trauma*; 7(1):022-034. DOI: 10.17352/ojt.000043.
22. Perrotta, G.(2022). The new Dysfunctional Personality Model of the Anxiety Matrix (DPM-AM): "Neurotic Personality Disorder" (NPD). *Ann Psychiatry Treatm*; 6(1):001-012. DOI: 10.17352/apt.000038.
23. Perlis, R.H.; Miyahara, S.; Marangell, L.B.; et al.(2004). Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Biological Psychiatry*; 55:875-881.
24. Monitor, M.(2010). *Bipolar disorder in the elderly*. *Vertex*; 21(92): 275-83. PMID 21188315.
25. Goldberg,(2009). T.E.; Kotov, R.; Lee, A.T., et al. The serotonin transporter gene and disease modification in psychosis: Evidence for systematic differences in allelic directionality at the 5-HTTLPR locus. *Schizophr Res*; 111: 103-8.
26. Daban, C.; Vieta, E.; Mackin, P.; et al.(2005). Hypothalamic-pituitary-adrenal axis and bipolar disorder. *Psychiatr Clin North Am*; 28:469-480.
27. Crowe, R.R.; Vieland, V.(1999). Report of the Chromosome 5 Workshop of the Sixth World Congress on Psychiatric Genetics. *Am J Med Genet*; 88: 229-32.
28. Kato, T.(2007). "Molecular genetics of bipolar disorder and depression", *Psychiatry Clin Neurosci*; 61(1): 3–19. PMID 17239033.
29. Reich, T.(1969). "Family history studies-V The genetics of Mania", *American Journal of Psychiatry*; 125: 1358–1369.
30. Baum, A.E.(2008). A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the aetiology of bipolar disorder. *Molecular Psychiatry*; 13(2):197-207. DOI: 10.1038/sj.mp.4002012.
31. Burton, P.R.(2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*; 447(7145): 661–678. DOI: 10.1038/nature05911.

32. Sklar, P.; Smoller, J.W.; Fan, J.; et al. (2008). Whole-genome association study of bipolar disorder. *Molecular Psychiatry*, DOI: 10.1038/sj.mp.4002151.
33. Ferreira, M.; O'Donovan, M.; Meng, Y. A.; et al. (2008). Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. *Nature Genetics*; 40:1056-1058.
34. Segurado, R.; Detera-Wadleigh, S.D.; Levinson, D.F.; et al. (2003). Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part III: *Bipolar Disorder*. *Am J Hum Genet*; 73:49-62. PMID 12802785.
35. McQuillin, A.; Bass, N.J.; Kalsi, G.; et al. (2006). "Fine mapping of a susceptibility locus for bipolar and genetically related unipolar affective disorders, to a region containing the C21ORF29 and TRPM2 genes on chromosome 21q22.3". *Mol Psychiatry*; 11(2): 134-142.
36. Xu, C.; Macciardi, F.; Li, P. P.; et al. (2006). "Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder". *Am J Med Genet B Neuropsychiatr Genet*; 141(1): 36-43.
37. Barrett T.B.; Hauger R.L.; Kennedy J.L.; et al. (2003). Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. *Molecular Psychiatry*; 8(5): 546-57. DOI: 10.1038/sj.mp.4001268.
38. Zandi P.P.; Belmonte P.L.; Willour V.L. (2008). Association study of Wnt signaling pathway genes in bipolar disorder. *Arch. Gen. Psychiatry*; 65(7): 785-93. DOI:10.1001/archpsyc.65.7.785.
39. Young, E. (2006). *New gene linked to bipolar disorder*. *New Scientist*.
40. Frans, E.; Sandin, S.; Reichenberg, A.; et al. (2008). Advancing Paternal Age and Bipolar Disorder. *Arch Gen Psychiatry*; 65(9):1034-1040.
41. Serretti A.; Mandelli L. (2008). The genetics of bipolar disorder: genome 'hot regions', genes, new potential candidates and future directions. *Mol Psychiatry*; 13(8):742-71. PMID 18332878.
42. Tondo L. (2017). Depression and mania in bipolar disorder. *Curr Neuropsychol*; 15(3): 353-358.
43. Paris J.; Black D.W. (2015). Borderline personality disorder and bipolar disorder: what is the difference and why does it matter? *J Nerv Ment Dis*; 203(1):3-7. DOI: 10.1097/NMD.0000000000000225.
44. Turchi F. (2016). Neural basis of social cognition in bipolar disorder. *Riv Psichiatr*; 51(5): 177-189.
45. Mertens, J.; Wang, Q.W. (2015). Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. *Nature*; 527: 95-99.
46. Solé B. (2017). Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies. *Int J Neuropsychopharmacol*; 20(8):670-680. DOI: 10.1093/ijnp/pyx032.
47. Van der Markt, A. (2019). Exploring the clinical utility of two staging models for bipolar disorder. *Bipolar Disord*. DOI: 10.1111/bdi.12825.
48. Vieta, E.; Franco, C. (2008) Advances in the treatment of mania: aripiprazole. *Actas Esp Psiquiatr*; 36: 158-164.
49. Mallinger, G.; Frank, E.; Thase, M. E. (2009). Revisiting the Effectiveness of Standard Antidepressants in Bipolar Disorder: Are Monoamine Oxidase Inhibitors Superior?, *Psychopharmacology bulletin*; 42(2): 64-74.
50. Bersani, F.S.; Girardi, N.; Sanna, L.; et al. (2013). Deep Transcranial Magnetic Stimulation for treatment-resistant bipolar depression: A case report of acute and maintenance efficacy. *Neurosci*. PMID 22827578.
51. Kennedy, D.; Koren, G. (1998). Valproic acid use in psychiatry: issues in treating women of reproductive age. *J Psychiatry Neurosci*; 23(4):223-8. PMID 9785701.
52. Behzadi, A. H. (2009). Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. *Acta Psychiatr Scand*; 1-5. DOI 10.1111/j.1600-0447.2009.01368.x.
53. Colom C. (2011) Keeping therapies simple: psychoeducation in the prevention of relapse in affective disorders. *British Journal of Psychiatry*; 198:338-340.
54. Kernberg O. (1967). Borderline Personality Organization. *Journal of American Psychoanalytic Association*. DOI: 10.1177/000306516701500309.
55. Oldham, J.M. (2004). *Borderline Personality Disorder: An Overview*. *Psychiatric Times*; 8(XXI).
56. Swartz, M.; Blazer, D.; George, L.; et al. (1990). *Estimating the Prevalence of Borderline Personality Disorder in the Community*. *Journal of Personality Disorders*; 4(3): 257-272. DOI: 10.1521/pedi.1990.4.3.257.
57. Skodol, A.E.; Bender, D.S. (2003). *Why are women diagnosed borderline more than men?* *Psychiatr Q*; 74(4): 349-60. DOI:10.1023/A:1026087410516.
58. Korzekwa, M.I.; Dell, P.F.; Links, P.S.; et al. (2008). *Estimating the prevalence of borderline personality disorder in psychiatric outpatients using a two-phase procedure*. *Compr Psychiatry*; 49(4): 380-6. DOI: 10.1016/j.comppsych.2008.01.007.
59. Grant B.F.; Chou S.P.; Goldstein R.B. (2008). Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*; 69(4): 533-45. DOI:10.4088/JCP.v69n0404.
60. Yeomans, F.E.; Levy, K.N. (2018). Borderline Personality Disorder. *Psychiatr Clin North Am*; 41(4): xiii-xv. DOI: 10.1016/j.psc.2018.09.001.
61. Bhome, R.; Fridrich, P. (2015). *Borderline Personality Disorder*. *Br J Hosp Med (Lond)*; 76(1):C14-6. DOI: 10.12968/hmed.2015.76.1.C14.
62. Manna, V.; Daniele, M.T.; Pinto M. (2004). Etiopathogenic factors of the *borderline personality disorder*. *Journal of Psychopathology*; 1(10).
63. Stiglmayr, C.E.; Grathwol, T.; Linehan, M.M.; et al. (2005). *Aversive tension in patients with borderline personality disorder: a computer-based controlled field study*. *Acta Psychiatr Scand*, 111(5): 372-9. DOI :10.1111/j.1600-0447.2004.00466.x.
64. Brown, M.Z.; Comtois, K.A.; Linehan, M.M. (2002). Reasons for suicide attempts and nonsuicidal self-injury in women with

- borderline personality disorder. *J Abnorm Psycho*; 111(1): 198-202. DOI: 10.1037/0021-843X.111.1.198.
65. Zanarini, M.C.; Frankenburg, F.R.; DeLuca, C.J.; et al. (1998). The pain of being borderline: dysphoric states specific to borderline personality disorder. *Harv Rev Psychiatry*; 6(4): 201-7. DOI: 10.3109/10673229809000330.
66. Gunderson, G.J.; Links, P.S. (2008). *Borderline Personality Disorder: A Clinical Guide*, 2nd, American Psychiatric Publishing Inc.
67. Soloff, P.H.; Lis, J.A.; Kelly, T. (1994). Self-mutilation and suicidal behavior in borderline personality disorder. *Journal of Personality Disorders*; 8(4): 257-67. DOI: 10.1521/pedi.1994.8.4.257.
68. Gardner, D.L.; Cowdry, R.W. (1985). Suicidal and parasuicidal behavior in borderline personality disorder. *Psychiatric Clinics of North America*; 8(2): 389-403. PMID 3895199.
69. Horesh, N.; Sever, J.; Apter, A. (2003). A comparison of life events between suicidal adolescents with major depression and borderline personality disorder. *Compr Psychiatry*; 44(4): 277-83. DOI: 10.1016/S0010-440X(03)00091-9.
70. Arntz, A. (2005). Introduction to special issue: cognition and emotion in borderline personality disorder. *Behav Ther Exp Psychiatry*; 36(3): 167-72. DOI: 10.1016/j.jbtep.2005.06.001.
71. Levy, K.N.; Meehan, K.B.; Weber, M.; et al. (2005). Attachment and borderline personality disorder: implications for psychotherapy. *Psychopathology*; 38(2): 64-74. DOI: 10.1159/000084813, PMID: 15802944.
72. Daley, S.E.; Burge, D.; Hammen, C. (2000). Borderline personality disorder symptoms as predictors of 4-year romantic relationship dysfunction in young women: addressing issues of specificity. *J Abnorm Psychol*; 109(3): 451-60. DOI: 10.1037/0021-843X.109.3.451.
73. Grant, B.F.; Chou, S.P.; Goldstein, R.B.; et al. (2008). Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*; 69 (4): 533-45. DOI: 10.4088/JCP.v69n040.
74. Swantje, D.M.; Philipsen, A. (2014). Common ground in Attention Deficit Hyperactivity Disorder (ADHD) and Borderline Personality Disorder (BPD) - review of recent findings. *Borderline Personality Disorder and Emotion Dysregulation*. DOI: 10.1186/2051-6673-1-3.
75. Philipsen, A. (2006). Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. *European Archives of Psychiatry and Clinical Neuroscience*; 256(1): 42-46. DOI: 10.1007/s00406-006-1006-2.
76. Giesen-Bloo, J.; van Dyck, R.; Spinhoven, P.; et al. (2006). Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. *Arch. Gen. Psychiatry*; 63(6): 649-58. DOI: 10.1001/archpsyc.636-649.
77. Poletti, M. (2009). Neurocognitive function in borderline personality disorder. *Rivista di Psichiatria*; 44(6).
78. Kandel, E. (2014). *Principi di Neuroscienze*. Casa Editrice Ambrosiana.
79. Brian, W.H.; Miller, J.D. (2015). Borderline Personality Traits and Brain Activity During Emotional Perspective Taking. *Personal Disord*; 6(4): 315-20. DOI: 10.1037/per0000130.
80. Keefe, J.R. (2020). Treatment selection in Borderline Personality Disorder between Dialectical Behavior Therapy and *Psychodynamic Psychiatric Management*. *Psychol Med*; 1-9. DOI: 10.1017/S0033291720000550.
81. Kenézloi, E. (2020). Transdiagnostic Study of Impulsivity Dimensions. Comparative Analysis of Impulsivity Profiles in Adult Attention Deficit Hyperactivity Disorder and Borderline Personality Disorder. *Psychiatr Hung*; 35(2): 136-145. PMID: 32191219.
82. Kors, S. (2020). The borderline feature of negative relationships and the intergenerational transmission of child maltreatment between mothers and adolescents. *Personal Disord*. DOI: 10.1037/per0000397.
83. Caligor, E.; Stern, B.L. (2020). Diagnosis, classification and assessment of narcissistic personality disorder within the framework of object relations theory. *J Pers Disord*; 34(suppl.): 104-121. DOI: 10.1521/pedi.2020.34.supp.104.
84. Lee, R.J. (2020). Narcissistic and borderline personality disorders: relationship with oxidative stress. *J Pers Disord*; 34 (suppl.): 6-24. DOI: 10.1521/pedi.2020.34.supp.6.
85. Zimmerman, M. (2020). Patients with borderline personality disorder and bipolar disorder: a descriptive and comparative study. *Psychol Med*; 1-12 DOI: 10.1017/S0033291720000215.
86. Davies, G. (2020). A Systematic Review of Structural MRI Investigations Within Borderline Personality Disorder: Identification of Key Psychological Variables of Interest Going Forward. *Psychiatry Res*, 2020; 286. DOI: 10.1016/j.psychres.112864.
87. Bertsch, K. (2013). Oxytocin and reduction of social threat hypersensitivity in woman with borderline personality disorder. *Am J Psychiatry*; 170: 1169-1177.
88. Witt, S.H. (2017). Genoma-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. *Transl Psychiatry*; 7(6): e1155. PMID: 28632202.
89. Amad, A. (2014). Genetics of borderline personality disorder: systematic review and proposal of an integrative model. *Neurosci Biobehav Rev*; 40: 6-19. DOI: 10.1016/j.neubiorev.2014.01.003.
90. Dimaggio, G.; Semerari, A. I disturbi di personalità. Modelli e trattamento. *Stati mentali*, (2015). metarappresentazione, *cicli interpersonali*. Laterza & Figli Spa.
91. Caligor, E.; Levy, K.N.; Yeomans, F.E. (2014). Narcissistic personality disorder: diagnostic and clinical challenges. *The American Journal of Psychiatry*, 2015; 172(5): 415-22. DOI: 10.1176/appi.ajp.14060723.
92. Nenadic, I.; Güllmar, D.; Dietzek, M.; et al. (2015). Brain structure in narcissistic personality disorder: A VBM and DTI pilot study. *Psychiatry Research: Neuroimaging*; 231: 184-186.
93. Kandel, E. (2019). *Principi di Neuroscienze*. Ambrosiana Ed.
94. Fossati, A.; Bersani, S. (2018). *Narcisismo patologico*. Raffaello Cortina Ed.

95. Pincus, A.L.; Lukowitsky, M.R.(2010). Pathological Narcissism and Narcissistic Personality Disorder. *Annu Rev Clin Psychol*; 6: 421-46. DOI: 10.1146/annurev.clinpsy.121208.131215.
96. Dieckmann, E.; Behary, W.(2015). Schema Therapy: An Approach for Treating Narcissistic Personality Disorder. *Fortschr Neurol Psychiatr*; 83(8): 463-77. DOI: 10.1055/s-0035-1553484.
97. Skodol, A.E.(2014). Narcissistic Personality Disorder in DSM-5. *Personal Disord*; 5(4): 422-7. DOI: 10.1037/per0000023, PMID: 23834518.
98. Lowen, A.(2013). Il narcisismo. Feltrinelli Ed.
99. Beck, A.T.(2016). *Cognitive Therapy of Personality Disorders*. Beck-Davis-Freeman Ed, Third Ed.;
100. French, J.H.; Shrestha, S.(2020). *Histrionic Personality Disorder*. StatePearls. PMID: 31194465.
101. Gabbard, G.O.(2007). *Psichiatria psicodinamica*. Raffaello Cortina Editore.
102. Novais, F.; Godinho, P.(2015). Historical roots of histrionic personality disorder. *Front Psycho*; 6:1463. DOI: 10.3389/fpsyg.2015.01463.
103. Ritzl, A.(2018). Facial emotion recognition deficits and alexithymia in borderline, narcissistic, and histrionic personality disorders. *Psychiatry Res*; 270: 154-159. DOI: 10.1016/j.psychres.2018.09.017.
104. Perrotta, G.; Eleuteri, S.; Grilli, S. Diagnostic parallels between borderline and bipolar patients in psychopathology: the genesis of disorders, similarities, differences, comorbidities, and a new proposal for an innovative psychometric instrument (Perrotta Border-Bipolar Profile Diagnostic Questionnaire, PBBD-Q). *In the process of publication*.
105. Perrotta, G.(2019). Depressive disorders: Definitions, contexts, differential diagnosis, neural correlates and clinical strategies. *Arch Depress Anxiety*; 5(2):9-33. DOI: 10.17352/2455-5460.000038.
106. Perrotta, G. Differential diagnosis in disorders with depressive symptoms: Exact clinical framing and proposal of the "Perrotta Depressive Symptoms Assessment". *In the process of publication*.
107. Perrotta, G.(2020). Borderline Personality Disorder: definition, differential diagnosis, clinical contexts and therapeutic approaches. *Ann Psychiatry Treatm*; 4(1):043-056. DOI: 10.17352/apt.000020.
108. Perrotta, G.(2021). Histrionic personality disorder: Definition, clinical profiles, differential diagnosis and therapeutic framework. *Arch Community Med Public Health*; 7(1):001-005. DOI: 10.17352/2455-5479.000123
109. Perrotta, G.(2020). Narcissism and psychopathological profiles: definitions, clinical contexts, neurobiological aspects and clinical treatments. *J Clin Cases Rep*; 4(85):12-25. DOI: 10.46619/joccr.2021.S5-1003.
110. Perrotta, G. "Perrotta Ego Hypertrophy Investigation Questionnaire (PEHI-Q)": development, regulation and validation of a psychometric tool to investigate the clinical aspects of Ego hypertrophy. *In the process of publication*.
111. Perrotta, G.; Marciano, A.(2022). The clinical boundary between deviant behavior and criminal conduct: From maladaptive positions to pathological dysfunctionality using the "Graded Antisociality Model" (GA-M), the "Antisocial Severity Scale" (AS-S) and "Perrotta-Marciano questionnaire on the grade of awareness of one's deviant and criminal behaviors" (ADCB-Q). *Ann Psychiatry Treatm*; 6(1):023-027. DOI: 10.17352/apt.000041.
112. Perrotta, G.; Marciano, A.; Piccininno, D.(2023). "Perrotta-Marciano questionnaire on the grade of awareness of one's deviant and criminal behaviors" (ADCB-Q-2) and the "Criminal Spectrum": Development, Updates, Regulation, and Validation of a new psychometric instrument. *Ann Psychiatry Treatm*; 7(1):042-053. DOI: 10.17352/apt.000052.
113. Yuhas, D.(2013). Throughout History, Defining Schizophrenia Has Remained a Challenge, Scientific American Mind.
114. Heinrichs, R.W.(2003). Historical origins of schizophrenia: two early madmen and their illness. *Journal of the History of the Behavioral Sciences*; 39(4): 349-63. DOI: 10.1002/jhbs.10152, PMID 14601041.
115. Noll, R.(2011). *American Madness: The Rise and Fall of Dementia Praecox*. Harvard University Press.
116. Noll, R.(2012). Whole Body Madness. *Psychiatric Times*; 29(12): 13-14.
117. Berrios, G.E.; Luque, R.; Villagran, J.(2003). Schizophrenia: a conceptual history. *International Journal of Psychology and Psychological Therapy*; 3(2): 111-140.
118. Picchioni, M.M.; Murray, R.M.(2007). Schizophrenia. *BMJ*; 335(7610): 91-5. DOI: 10.1136/bmj.39227.616447.BE.
119. Kumra, S.; Shaw, M.; Merka, P.; et al.(2001). Childhood-onset schizophrenia: research update. *Canadian Journal of Psychiatry*; 46(10): 923-30. PMID 11816313.
120. Hassett, A.(2005). *Psychosis in the Elderly*. Taylor and Francis Press.
121. Jablensky, A.; Sartorius, N.; Ernberg, G.; et al(1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. *Psychological Medicine Monograph Supplement*; 20: 1-97. DOI: 10.1017/S0264180100000904.
122. Kirkbride, J.B.; Fearon, P.; Morgan, C.; et al.(2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. *Archives of General Psychiatry*; 63(3): 250-8. DOI: 10.1001/archpsyc.63.3.250.
123. O'Donovan, M.C.; Craddock, N.J.; Owen, M.J.(2009). Genetics of psychosis: insights from views across the genome. *Hum. Genet*; 126(1): 3-12. DOI: 10.1007/s00439-009-0703-0.
124. Goff, D.C.(2004). Folate, homocysteine, and negative symptoms in schizophrenia. *Am J Psychiatry*; 161(9): 1705-8. DOI: 10.1176/appi.ajp.161.9.1705.
125. Lingiardi, V.(2011). *La personalità e i suoi disturbi*. Il Saggiatore Ed.
126. Siever, L.J.(1992). Schizophrenia spectrum disorders. *Review of Psychiatry*; 11:25-42.
127. Malaspina, D.(2013). Schizoaffective disorder in the DSM-5. *Schizophrenia Research*; 150(1): 21-5. DOI: 10.1016/j.schres.2013.04.026.

128. Perrotta, G.(2020). Psychotic spectrum disorders: definitions, classifications, neural correlates and clinical profiles. *Ann Psychiatry Treatm.*; 4(1):070-084. DOI: 10.17352/apt.000023.
129. Perrotta, G.(2021). The state of consciousness: from perceptual alterations to dissociative forms. Defining,

- neurobiological and clinical profiles. *J Neuro Neurol Sci Discord*; 7(1):006-018. DOI: 10.17352/jnnsd.000042.
130. Perrotta, G.(2019). Delusions, paranoia and hallucinations: definitions, differences, *clinical contexts and therapeutic approaches*. *CJNE*; 1(4):22-28.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

Submit Manuscript

DOI:[10.31579/2637-8892/308](https://doi.org/10.31579/2637-8892/308)

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/psychology-and-mental-health-care>